The Safety and Efficacy of Roflumilast Foam in HS
NCT07263230
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hidradenitis Suppurativa (HS)
Interventions
DRUG:
Roflumilast 0.3% topical foam
Sponsor
Beth Israel Deaconess Medical Center